Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Open Label Extension Study of Fostamatinib in Warm Antibody Autoimmune Hemolytic Anemia
2019-001882-34Phase 3Completed
- Sponsor
- Rigel Pharmaceuticals, Inc.
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fostamatinib in warm autoimmune hemolytic anemia (wAIHA), sponsored by Rigel Pharmaceuticals, Inc. Started Dec 2019; status: completed.
02
Drugs
fostamatinib
03
Conditions
warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on 2019-001882-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001882-34.